S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

$14.55
+0.41 (+2.90%)
(As of 03/27/2024 ET)
Today's Range
$14.10
$14.89
50-Day Range
$14.14
$18.68
52-Week Range
$12.60
$30.85
Volume
254,383 shs
Average Volume
371,904 shs
Market Capitalization
$876.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.44

Pliant Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.0% Upside
$48.44 Price Target
Short Interest
Bearish
11.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
1.01mentions of Pliant Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$869,857 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.77) to ($3.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

224th out of 939 stocks

Pharmaceutical Preparations Industry

97th out of 435 stocks

PLRX stock logo

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Stock Price History

PLRX Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
PLRX Oct 2024 30.000 call
PLRX Oct 2024 7.500 put
PLRX Jul 2024 20.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
PLRX Jul 2024 10.000 put
Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen
PLRX Mar 2024 10.000 put
Pliant Therapeutics Inc Ordinary Shares PLRX
PLRX Mar 2024 25.000 call
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/27/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.44
High Stock Price Target
$63.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+233.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-161,340,000.00
Net Margins
-2,872.79%
Pretax Margin
-10,211.14%

Debt

Sales & Book Value

Annual Sales
$1.58 million
Book Value
$7.91 per share

Miscellaneous

Free Float
56,866,000
Market Cap
$876.49 million
Optionable
Optionable
Beta
1.13
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 57)
    M.D., Ph.D., President, CEO & Director
    Comp: $1.06M
  • Dr. Keith Lamont Cummings M.B.A. (Age 47)
    M.D., Chief Financial Officer
    Comp: $662.34k
  • Mr. Mike Ouimette J.D. (Age 51)
    General Counsel & Corporate Secretary
    Comp: $591.05k
  • Mr. Johannes P. Hull (Age 49)
    Chief Business Officer
    Comp: $631.64k
  • Dr. Éric Lefebvre M.D. (Age 60)
    Chief Medical Officer
    Comp: $763.49k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer

PLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price target for 2024?

10 analysts have issued 1-year target prices for Pliant Therapeutics' stock. Their PLRX share price targets range from $38.00 to $63.00. On average, they predict the company's share price to reach $48.44 in the next year. This suggests a possible upside of 233.0% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2024?

Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 19.7% and is now trading at $14.55.
View the best growth stocks for 2024 here
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.06. The business had revenue of $1.61 million for the quarter, compared to analyst estimates of $2.50 million. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative trailing twelve-month return on equity of 31.15%.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.32%), Price T Rowe Associates Inc. MD (6.32%), First Light Asset Management LLC (6.00%), Vanguard Group Inc. (5.12%), Vanguard Group Inc. (5.09%) and Blue Owl Capital Holdings LP (5.02%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends
.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners